Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature

Jinxin Zheng¹, Minggui Deng¹, Xiaoliang Qiu², Zhong Chen¹, Duoyun Li¹, Xiangbin Deng¹, Qiwen Deng¹ and Zhijian Yu¹*

Abstract

Background: Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. However, reported cases of telbivudine leading to multiple organ failure are rare. Here, we report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure.

Case presentation: A 30-year-old Chinese man with hepatitis B virus infection received antiviral treatment with 600 mg of telbivudine daily for more than 11 months. He developed progressive weakness and myalgia, and subsequently experienced palpitations, chest tightness, lethargy, hypotension, and hypoxemia. Blood tests showed markedly elevated levels of alanine aminotransferase (955 U/L), aspartate aminotransferase (1375 U/L), blood urea nitrogen (14.9 mmol/L), creatine kinase (peak at 8050 U/L), and blood lactate (>20.0 mmol/L). His symptoms improved after continuous renal replacement therapy and short-term methylprednisolone treatment. Hyperbaric oxygen therapy, physical therapy, and rehabilitation for more than 2 months led to recovery of muscle strength to the normal range.

Conclusions: We conclude that continuous renal replacement and steroid therapies play key roles in stabilizing telbivudine-induced severe rhabdomyolysis, lactic acidosis, and multiple organ failure. Hyperbaric oxygen, physical therapy, and rehabilitation may aid in functional recovery after the acute phase of lactic acidosis and organ failure.

Keywords: Hepatitis B, Lactic acidosis, Multiple organ failure, Rhabdomyolysis, Telbivudine

Background

One of the most common infectious diseases in the world, chronic hepatitis B is a serious public health problem in China [1]. Pathogenesis of hepatitis B virus (HBV) is still not completely clear. Currently, the standard therapy for chronic hepatitis B is antiviral treatment with nucleoside analogs, including lamivudine, adefovir, entecavir, telbivudine, or tenofovir.

In October 2006, the L-nucleoside analog telbivudine at a dose of 600 mg/day was approved for HBV treatment. Compared to lamivudine, telbivudine showed a lower rate of drug resistance and higher rate of hepatitis B envelope antigen (HBeAg) seroconversion [2]. However, a clinical trial revealed myopathy to be an adverse effect [2]. Telbivudine therapy led to grade 3/4 creatine kinase (CK) elevation in 0.3 to 5% of patients [3], as well as accelerated muscle toxicity in patients with pre-existing muscle damage [4]. Telbivudine can also cause fatal rhabdomyolysis and lactic acidosis [5, 6].

Telbivudine-associated elevation of CK levels, myopathy, hyperlactatemia, and rhabdomyolysis have been frequently reported, whereas reports of multiple organ failure (MOF) are rare. Here, we describe a patient who was treated for 11 months with telbivudine for HBV and subsequently developed rhabdomyolysis, lactic acidosis, and MOF.
Case presentation
A 30-year-old Chinese man who had been HBeAg-positive for at least 10 years received telbivudine (Novartis Pharma AG, Basel, Switzerland) at a dosage of 600 mg once daily for 1 year before he presented to our hospital. He had no previous history of antiviral therapy. After 11 months of treatment, he complained of progressive pain and weakness in his lower extremities, poor appetite, nausea, and vomiting. Biochemical tests showed that his serum CK level had increased to 1000 U/L. Telbivudine was stopped immediately.

He was admitted to a ward with worsening symptoms. Laboratory tests were positive for hepatitis B surface antigen and HBeAg, but HBV deoxyribonucleic acid (DNA) was not detected. His serum CK level was elevated to 1220 U/L. Electromyography indicated slow nerve conduction velocity in both lower extremities. One week after admission, he developed shortness of breath, dyspnea, chest pain, malaise, and cold limbs with terminal cyanosis. The muscle strengths of his upper and lower extremities on the Medical Research Council scale were 2/5 and 1/5, respectively.

He was transferred to our intensive care unit, where he was found to have hypotension with a blood pressure of 82/43 mmHg. Oxygen saturation decreased to 80% despite nasal oxygen inhalation at a flow rate of 5 L/minute. Biochemical tests showed increased levels of alanine aminotransferase (ALT, 955 U/L), aspartate aminotransferase (AST, 1375 U/L), blood urea nitrogen (BUN, 14.9 mmol/L), serum CK (peak at 8050 U/L), and lactate dehydrogenase (LDH, 2040 U/L; Table 1). He was treated with telbivudine, 12 to 14% reported fatigue and malaise, 9% reported asymptomatic hyper-CK-emia, and 0.5% reported myopathy during treatment [12].

Male sex, younger age, and HBeAg negativity were independent predictors of elevated CK levels in patients receiving telbivudine treatment in China [3]. Recently, Chen et al. found that male sex and lower baseline estimated glomerular filtration rate were significant risk factors for elevation of CK levels during telbivudine treatment [13]. In our patient, the CK level was markedly elevated (peak at 8050 U/L). Male sex may have been associated with prolonged exercise or acceleration of pre-existing muscle damage, a phenomenon that was reported previously [4].

Several studies reported telbivudine-related myopathy and neuropathy, but these side effects were typically mild and reversible [14–17]. To date, reports of telbivudine-induced severe side effects, such as rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF, have been very rare. Jin et al. described a 36-year-old man who developed severe refractory lactic acidosis during telbivudine monotherapy. He fully recovered after 16 weeks of hemodialysis and glucocorticosteroid treatment [6]. Wang et al. described a patient who developed hyperlactatemia during telbivudine treatment and was
| Parameter | 1 d | 2 d | 3 d | 4 d | 5 d | 6 d | 7 d | 8 d | 9 d | 10 d |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| TB (μmol/L) | 13.9 | 15.1 | 19.1 | 22.5 | –   | 14.9 | –   | 14.8 | 12.3 | 9.9  |
| ALT (U/L)  | 25.0 | 80.0 | 350.0 | 955.0 | 1660 | 73.0 | 480.0 | 32.0 | 34.0 | 250  |
| AST (U/L)  | 74.0 | 106.0 | 216.0 | 1375.0 | 217.0 | 1360 | 290  | 250  | 270  | 28.0 |
| ALB (g/L)  | 38.0 | 32.3 | 35.4 | 33.7 | –   | 31.8 | –   | 38.8 | 41.0 | 37.8 |
| LDH (U/L)  | 439.0 | 438.0 | 494.0 | 2040.0 | 724.0 | 693.0 | 548.0 | 368.0 | 239.0 | –   |
| CK (U/L)   | 12200 | 11480 | 4160.0 | 35680 | 8050.0 | 24400 | 1240 | 73.0 | 560  | 54.0 |
| CK-MB (U/L)| 17.0 | 22.0 | 13.6 | 369  | 43.3 | 263  | 134  | 12.3 | 96.0 | 9.2  |
| Lac (mmol/L)| 2.2 | 20.0 | 5.1 | 2.3 | 2.3 | 2.3 | 2.2 | 1.5 | 14.0 | –   |
| WBC (× 10^9/L)| 6.7 | 21.1 | 14.0 | 134  | 10.5 | 127  | 122  | 11.3 | 100  | 7.2  |
| RBC (× 10^12/L)| 4.2 | 4.2 | 2.9 | 2.8 | 2.8 | 3.0 | 3.5 | 3.7 | 4.1  | 4.0  |
| PLT (× 10^9/L)| 21.0 | 21.0 | 48.0 | 48.0 | 46.0 | 820  | 185.0 | 182.0 | 2170 | 187.0 |
| BUN (mmol/L)| 3.6 | 14.9 | 11.6 | 105  | 9.0  | 55.0 | 43.0 | 5.1  | 46.0 | 21.9 |
| PT (seconds)| –   | 16.7 | 16.5 | 169  | 17.3 | 147  | 129  | –   | –   | –   |
| UMS (level)| 4.0 | 2.0 | 3.0 | 3.0  | 3.0  | 3.0  | 3.0  | 3.0  | 4.0  | 5.0  |
| LMS (level)| 3.0 | 1.0 | 1.0 | 1.0  | 1.0  | 1.0  | 2.0  | 3.0  | 3.0  | 3.0  |

Normal ranges are given in parentheses as follows: ALB albumin (35–55 g/L), ALT alanine aminotransferase (5–45 U/L), AST aspartate aminotransferase (5–45 U/L), BUN blood urea nitrogen (1.7–7.1 mmol/L), CK creatine kinase (10–195 U/L), d days, LDH lactate dehydrogenase (80–285 U/L), LMS muscle strength of lower extremities (according to the Medical Research Council scale), - not detected, CK-MB cardiac creatinine phosphokinase isoenzyme (0–24 U/L), Lac lactate (0–2.2 mmol/L), PLT platelet (100–300 × 10^9/L), PT prothrombin time (10–14.5 seconds), RBC red blood cell (4.0–5.5 × 10^12/L), TB total bilirubin (1.7–22.5 μmol/L), UMS muscle strength of upper extremities (according to the Medical Research Council scale), WBC white blood cell (4.0–10.0 × 10^9/L).
successfully treated with continuous venovenous hemodiafiltration [18]. However, another patient with telbivudine-induced rhabdomyolysis developed acute renal failure and metabolic acidosis by day 18 after admission and, despite hemofiltration, died within 24 hours of developing these symptoms [5]. Table 2 lists characteristics of previously reported patients who developed severe adverse effects during telbivudine treatment. As these conditions are potentially fatal, immediate hemodialysis and glucocorticosteroid therapy are indicated.

The risk factors for telbivudine-induced rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF are still unclear. A previous study found telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage [4]. Another research found that in liver transplant recipients, telbivudine-induced polyneuropathy/myopathy maybe due to diabetes [19]. When it comes to lactic acidosis or hyperlactatemia caused by telbivudine, Jin et al. found that a case with telbivudine-induced lactic acidosis had a history of hypokalemic periodic paralysis, but the relationship between the pre-existence of myopathy and telbivudine treatment was uncertain [6]. However, like the case of another previous study, our patient also had no heavy exercise or heavy drinking, and had no history of diabetes mellitus [18]. Thus the risk factors for telbivudine-induced lactic acidosis or MOF are still ambiguous and need to be further explored. The case in this study developed severe telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF; the reason maybe that his elevated CK levels and rhabdomyolysis were not discovered in a timely manner because he received no regular reexamination. Although telbivudine was stopped, the rhabdomyolysis continue progressed and developed to lactic acidosis and MOF. So during the telbivudine treatment for HBV, except for detecting the possible risk factors associated with telbivudine-induced rhabdomyolysis or lactic acidosis, monitoring for muscular abnormalities, CK levels, and rhabdomyolysis is also very important for these cases.

Mechanisms underlying telbivudine-induced myopathy and lactic acidosis remain unclear. Whereas some studies showed that telbivudine may cause mitochondrial toxicity and dysfunction, which might lead to myopathy and lactic acidosis [20], in vitro studies indicated no effect of the drug on lactic acid production, mitochondrial DNA content, or morphology [21]. Recently, Hernández-Lain et al. identified a novel RRM2B gene variant associated with telbivudine-induced mitochondrial myopathy [22]. Therefore, the mechanism remains to be elucidated.

In this report, we describe the case of 30-year-old man with telbivudine-induced severe side effects, including rhabdomyolysis, lactic acidosis, and MOF. His condition deteriorated rapidly after admission, with shortness of breath, muscle weakness, hypotension, hypoxia, and elevated CK levels within 1 week. Several reasons may account for the severe effects. Physicians may not have
paid enough attention to the elevation of CK levels and myopathy during gastroenterology follow up. Underlying causes of his worsening condition were not immediately confirmed. CRRT and immunosuppressive therapy may not have been started as early as possible. Despite delays in diagnosis and treatment, our patient improved after CRRT and methylprednisolone therapy, which played key roles in the telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF.

The role of glucocorticoid in the treatment of telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF are unclear. In this study, we found our patient’s elevated lactate level in his blood and rhabdomyolysis improved significantly after CRRT and methylprednisolone therapy. But in another study, a patient with telbivudine-induced rhabdomyolysis only received hemofiltration therapy, the patient did not receive glucocorticoid therapy, and died within 24 hours [5]. Thus, the CRRT and glucocorticoid therapy may play key roles in stabilizing telbivudine-induced severe rhabdomyolysis, lactic acidosis, and MOF. Another study found that low-dose glucocorticoid for a short period of time may help to return the blood lactate level to normal, and the current study also indicated that CRRT combined with methylprednisolone therapy help to reduce the blood lactate level to normal.

However, we found that low-dose glucocorticoid therapy could not improve the poor muscle strength of our patient [6]. HBO therapy, which is very helpful in optic neuritis [23], can be used to treat myositis [24], although there have been no reports of HBO therapy for telbivudine-induced myositis or neuritis. A biopsy confirmed multiple nerve root inflammation and polymyositis in our patient, who subsequently received HBO therapy for more than 1 month and PTR for more than 2 months. Our patient gradually recovered, indicating that these interventions may be helpful in the treatment of telbivudine-induced myositis and neuritis. To the best

Table 2 Literature review of patients who developed severe adverse events during telbivudine treatment

| Patient number | Age (years) | Adverse effect | Liver condition | Tx time (months) | Peak CK (U/L) | Peak lactate (mmol/L) | Prognosis | Reference |
|----------------|-------------|----------------|-----------------|------------------|--------------|----------------------|-----------|-----------|
| 1              | 27          | Myopathy       | CHB             | 3                | 3243         | –                    | Resolved  | [4]       |
| 2              | 67          | Myopathy       | CHB             | 20               | 4775         | –                    | Resolved  | [14]      |
| 3              | 25          | Myopathy       | CHB             | 6                | 1614         | –                    | Resolved  | [15]      |
| 4              | 28          | Myopathy       | CHB             | 9                | 788          | –                    | Resolved  | [16]      |
| 5              | 25          | Myopathy       | CHB             | 13               | 2592         | –                    | Resolved  | [16]      |
| 6              | 68          | Myopathy       | CHB             | 2                | 237          | –                    | Resolved  | [17]      |
| 7              | 35          | Rhabdomyolysis, lactic acidosis | CHB | 11 | 3683 | > 12.0 | Resolved | [6] |
| 8              | 26          | Lactic acidosis | CHB             | 12               | 4151         | 11.3                 | Resolved  | [18]      |
| 9              | 30          | Rhabdomyolysis, lactic acidosis, organ failure | CHB | 11 | 8050 | > 20.0 | Resolved | This paper |
| 10             | 48          | Rhabdomyolysis, metabolic acidosis, organ failure | Cirrhosis | 9 | 3246 | – | Death | [5] |

CHB chronic hepatitis B, CK creatine kinase, Tx treatment, lactate mmol/L × 9.608 = mg/dL
of our knowledge, the patient in this study was the first case which experienced myopathy, rhabdomyolysis, lactic acidosis, shock, and MOF during telbivudine treatment and be treated successfully.

Conclusions
Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, lactic acidosis, and even MOF. Risk of severe side effects is especially pronounced in younger male or highly active patients. CRRT and glucocorticoid therapy should be given as soon as possible after diagnosis, while HBO and PTR may be helpful for myositis and neuritis. Patients should be closely monitored for CK levels, myopathic symptoms, and blood lactate levels during telbivudine treatment.

Abbreviations
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; CK: Creatine kinase; CRRT: Continuous renal replacement therapy; HBeAg: Hepatitis B envelope antigen; HBO: Hyperbaric oxygen; HBV: Hepatitis B virus; HCO3: Bicarbonate; LDH: Lactate dehydrogenase; MOF: Multiple organ failure; PaCO₃: Partial pressure of carbon dioxide in arterial blood; PO₂: Partial pressure of oxygen; PTR: Physical therapy and rehabilitation

Acknowledgements
We thank Professor Jiming Zhang (Department of Infectious Diseases, Huashan Hospital, Fudan University) for helpful suggestions on the manuscript.

Funding
This work was supported by grants from Shenzhen Scientific Research Program of the People's Republic of China (No. JCYJ20130402151227180, JCYJ20130402151227167).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
JZ followed this case and drafted the manuscript; MD and ZC helped for the muscle biopsy operation. XD guided the HBO therapy, physiotherapy, and follow up of this case; DL followed the laboratory tests and completed follow up of this case; XQ, QD, and ZY revised this paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved and consented to participate by the Ethics committee of Shenzhen Nanshan Hospital, Shenzhen University.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Infectious Diseases and Shenzhen Key Lab for Endogenous Infection, Shenzhen Nanshan Hospital, Shenzhen University, No 89, Taoyuan Road, Nanshan District, Shenzhen 518052, China. 2Department of Medicine, Marshall University School of Medicine, 1600 Medical Center Drive, Huntington, WV 25701, USA.

Received: 21 April 2017 Accepted: 25 October 2017

References
1. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J Viral Hepat. 2010;17:10–7.
2. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–95.
3. Zou XL, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18:892–6.
4. Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J. 2010;7:323–5.
5. Dang SS, Gao N, Zhang X, Jia XL. Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis. Am J Med Sci. 2011;342:73–5.
6. Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol. 2013;19:5575–80.
7. Nach K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009;26:155–69.
8. Hernandez-Santiago B, Placioli L, Cretton-Scott E, et al. Pharmacology of beta-L-thymidine and beta-L-2′-deoxyctydine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother. 2002;46:1728–33.
9. Li CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–88.
10. Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13:6150–5.
11. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787–91.
12. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007;29:635–53.
13. Chen L, Cheng C, Chen BC, Zhao Y, Zhang JM, Wang B. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol. 2016;72:235–41.
14. Caroleo B, Galasso O, Staltari O, et al. Muscular damage during telbivudine treatment in a chronic hepatitis B patient. Muscles Ligaments Tendons J. 2011;1:57–60.
15. Wang M, Da YW, Cai HD, Lu Y, Wu LY, Jia JP. Telbivudine myopathy in a patient with chronic hepatitis B. Int J Clin Pharm. 2012;34:422–5.
16. Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol. 2013;19:82–6.
17. Lee SW, Jang JH, Kim BJ. Dysphagia could be the first presenting symptom of telbivudine-induced myopathy. J Gastroenterol Hepatol. 2013;28:1276–80.
18. Wang YH, Wu BQ, Liu H. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B. Int J Clin Pharm. 2012;34:422–5.
19. Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol. 2013;19:82–6.
20. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2007;45:1111–4.